ascopubs.org

Targeting the mTOR pathway in ovarian cancer.

Prognostic value of hedgehog signaling in cervical carcinoma. Background: Although improvements in the treatment of ovarian cancer have increased the global prognosis, the metastatic disease is still ...

Sensei Biotherapeutics stock soars 230% after Faeth deal

Sensei Biotherapeutics, Inc. SNSE surged on Wednesday following the company’s announcement of its acquisition of Faeth Therapeutics Inc. and a concurrent $200 million private investment. The ...
Medical Xpress

Unexpected link between most common cancer drivers may yield more effective drugs

Cells muster a protein, called p53, which acts inside the cell nucleus to respond to stress, but mutations of the gene that produces p53 are the most frequent genetic abnormalities in cancer.

Sensei Biotherapeutics Announces Acquisition of Faeth Therapeutics and $200 Million Concurrent Private Placement

Sensei Biotherapeutics, Inc. (Nasdaq: SNSE) today announced that it has acquired Faeth Therapeutics Inc. ("Faeth"), a clinical-stage biotechnology company developing multi-node therapies that target ...
ascopubs.org

Effect of PI3K inhibitor LY294002 combined with RAD001, a mTOR specificity inhibitor, on proliferation and apoptosis of triple-negative breast cancer cell lines MDA-MB-231 ...

Metronomic methotrexate and cyclophosphamide after carboplatin included adjuvant chemotherapy in triple-negative breast cancer: A phase III study. This is an ASCO Meeting Abstract from the 2015 ASCO ...